Lapatinib: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
David Canner (talk | contribs)
7,699 edits
No edit summary
David Canner (talk | contribs)
7,699 edits
No edit summary
Line 7: Line 7:
* 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref>
* 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref>
* Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast cancer.  
* Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast cancer.  
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders


===Mechanism of Action===
===Mechanism of Action===
Line 15: Line 15:
{| class="wikitable" border="1" width="55%" style="text-align:center"
{| class="wikitable" border="1" width="55%" style="text-align:center"
|-
|-
!  colspan="4" align="center"| EGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages<ref>PMID:16609030</ref><ref>PMID:17482782</ref><ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref>
!  colspan="4" align="center"| EGFR Inhibitor [[Pharmacokinetics]] Comparison at Equivalent Dosages<ref>PMID:16609030</ref><ref>PMID:17482782</ref><ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref>
|-
|-
! Parameter
! Parameter
Line 22: Line 22:
! [[Lapatinib]] <br/>(Tykerb)
! [[Lapatinib]] <br/>(Tykerb)
|-
|-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)  
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)  
! 2.0
! 2.0
! 5.4
! 5.4
! 4
! 4
|-
|-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)  
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)  
! 69.6
! 69.6
! 130
! 130
! 115
! 115
|-
|-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! 99
! 99
! 59
! 59
! Variable
! Variable
|-
|-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
! 93
! 93
! 90
! 90
! 99
! 99
|-
|-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 9.4
! 9.4
! 26.9
! 26.9
! 9.6
! 9.6
|-
|-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! 20577
! 20577
! 3850
! 3850
Retrieved from "https://proteopedia.org/Lapatinib"